India’s Sun Pharmaceutical Industries Ltd Gets US Nod to Sell Cancer Drug

September 23, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

NEW DELHI, Sept 23 (Reuters) - India's Sun Pharmaceutical Industries said on Tuesday it had approval from the U.S. Food and Drug Administration to market generic versions of Paraplatin, which is indicated for the treatment of ovarian cancer.

Twitter
LinkedIn
Facebook
Email
Print

FDA Approvals Asia